The Pharmacology of Second Generation Neuroleptics

21
WPA WPA The Pharmacology The Pharmacology of Second of Second Generation Generation Neuroleptics Neuroleptics

description

The Pharmacology of Second Generation Neuroleptics. Structure of Serotonin. Distribution of Serotonin. Combined Serotonin and Dopamine Pathways. Risperidone. Clozapine. Olanzapine. D 2. D 2. D 2. 10 1 0.1 0.01 0.001 0.0001. 10 1 0.1 0.01 0.001 0.0001. 10 1 0.1 0.01 0.001 - PowerPoint PPT Presentation

Transcript of The Pharmacology of Second Generation Neuroleptics

Page 1: The Pharmacology of Second Generation Neuroleptics

WPAWPA

The Pharmacology of The Pharmacology of Second Generation Second Generation

NeurolepticsNeuroleptics

Page 2: The Pharmacology of Second Generation Neuroleptics

WPAWPA

Structure of SerotoninStructure of Serotonin

Page 3: The Pharmacology of Second Generation Neuroleptics

WPAWPA

Distribution of SerotoninDistribution of Serotonin

Page 4: The Pharmacology of Second Generation Neuroleptics

WPAWPA

Combined Serotonin and Combined Serotonin and Dopamine PathwaysDopamine Pathways

Page 5: The Pharmacology of Second Generation Neuroleptics

WPAWPA

Receptor Binding Affinities Receptor Binding Affinities of Three Atypical Antipsychoticsof Three Atypical Antipsychotics

Kasper, Data from:Schotte et al., 1996

Olanzapine

5-HT2A

5-HT2C

AChM

H1

1

D2101

0.10.01

0.0010.0001

D2

5-HT2A

5-HT2C

AChM

H1

2 1

Risperidone

101

0.10.01

0.0010.0001

Clozapine

5-HT2A

5-HT2C

AChM

H1

2 1

D2101

0.10.01

0.0010.0001

(No data availablefor 2-receptors)

Page 6: The Pharmacology of Second Generation Neuroleptics

WPAWPA

Neuroleptic Receptor Neuroleptic Receptor PiesPies

ClozapineClozapine OlanzapineOlanzapineQuetiapineQuetiapineDD11

DD22

5-HT5-HT2A2A

5-HT5-HT1A1A

AA11

AA22

HH11

MuscarinicMuscarinicZiprasidoneSertindole Risperidone Haloperidol

Page 7: The Pharmacology of Second Generation Neuroleptics

WPAWPA

Receptor-pies Reflect an Abstract Concept In Humans the Effects Are a Function of Dose

5-HT2

5-HT2D2 D2

B B B B BB

BB

B

B

BB

BB

BB B B B B B B B B B B B B B

J J J J J J J J JJ

JJ

J

J

JJ

JJ

J J J J J J J J J J J

0

10

20

30

40

50

60

70

80

90

100

Dose of the S2/D2 medication

5-HT2 5-HT2

5-HT2

D2D2

D2

Page 8: The Pharmacology of Second Generation Neuroleptics

WPAWPA

Using Imaging Tools to Using Imaging Tools to Develop Rational Develop Rational Dosing StrategiesDosing Strategies

Page 9: The Pharmacology of Second Generation Neuroleptics

WPAWPA

Page 10: The Pharmacology of Second Generation Neuroleptics

WPAWPA

D2 Receptor BindingD2 Receptor Binding•The ligand C11-The ligand C11-Raclopride is Raclopride is injected prior to injected prior to PET study.PET study.Areas of high Areas of high uptake (high D2 uptake (high D2 occupancy) are occupancy) are shown in red.shown in red.

Page 11: The Pharmacology of Second Generation Neuroleptics

WPAWPA

Haloperidol and D2 Occupancy

11C-Raclopride PET Scan

Coregistered MRI Scan

BeforeTreatment

Haloperidol2 mg/d (74% Occ.)

11C-Raclopride PET Scan

Page 12: The Pharmacology of Second Generation Neuroleptics

WPAWPA

DD22 Occupancy Predicts Clinical Occupancy Predicts Clinical ResponseResponse

Striatal D2 Occupancy

<65% > 65%

Per

cent

Res

pond

ers

(CG

I)

0

20

40

60

80

100

Non RespondersResponders

Kapur et al. Am. J Psychiatry, 2000

D2 occupancy predicts response on CGI (p < 0.001)Predicts change in positive symptoms (p = 0.07)

Page 13: The Pharmacology of Second Generation Neuroleptics

WPAWPA

DD22 Occupancy Predicts EPS/akathisia Occupancy Predicts EPS/akathisia

Individual Subjects

D2

Occ

upan

cy

Subjects withEPS or akathisia

NO subject < 78%showed EPS/akathisia

Kapur et al. American Journal of Psychiatry, 2000.

78%

Page 14: The Pharmacology of Second Generation Neuroleptics

WPAWPA

DD22 Occupancy Predicts Occupancy Predicts Prolactin ElevationProlactin Elevation

30 40 50 60 70 80 90 100Dopamine D 2 Receptor Occupancy

0

20

40

60

80

100

120Pr

olac

tin L

evel

s (n

g/m

l)

D2 occupancy predicts prolactin elevation (F1,20 = 7.3, p < 0.01)

2 of 15 show prolactin

elevation below 72%D2

5 of 6 show prolactin

elevation above 72%D2

Page 15: The Pharmacology of Second Generation Neuroleptics

WPAWPA

0 2 4 6 8 10 12Risperidone dose mg/day

0

10

20

30

40

50

60

70

80

90

100

Rec

epto

r Occ

upan

cy (%

)

D2 Occupancy5-HT2 Occupancy

Risperidone 5-HTRisperidone 5-HT22 & D & D22 OccupancyOccupancy

EPS

Threshold for Response

Threshold for EPS

Kapur, Zipursky and Remington, American Journal of Psychiatry, 1999.

Page 16: The Pharmacology of Second Generation Neuroleptics

WPAWPA

0 10 20 30 40 50Olanzapine dose mg/day

0

10

20

30

40

50

60

70

80

90

100

Rec

epto

r Occ

upan

cy (%

)

LegendD2 data5-HT2 data

Olanzapine 5-HTOlanzapine 5-HT22 & D & D22 OccupancyOccupancy

EPS + Prolactin *

EPS and/or prolactin elevation

Kapur, Zipursky and Remington, American Journal of Psychiatry, 1999.

Page 17: The Pharmacology of Second Generation Neuroleptics

WPAWPA

Practical Aspects Practical Aspects of Treatmentof Treatment

Page 18: The Pharmacology of Second Generation Neuroleptics

WPAWPA

Practical IssuesPractical Issues• DosageDosage• Use of AnticholinergicsUse of Anticholinergics• Oral vs. Depot NeurolepticsOral vs. Depot Neuroleptics• Reducing or Discontinuing Reducing or Discontinuing

MedicationMedication• Long-term OutcomeLong-term Outcome• Early interventionEarly intervention

Page 19: The Pharmacology of Second Generation Neuroleptics

WPAWPA

Can Early Intervention Can Early Intervention Prevent Disease Prevent Disease

Progression?Progression?• Early diagnosis is difficultEarly diagnosis is difficult• It is also hampered by stigmaIt is also hampered by stigma• There is minimal to no evidence There is minimal to no evidence

for a direct toxic brain effect of for a direct toxic brain effect of untreated psychosisuntreated psychosis

• However, the psychological However, the psychological impact of untreated psychosis impact of untreated psychosis may be significantmay be significant

Page 20: The Pharmacology of Second Generation Neuroleptics

WPAWPA

Psychosocial Psychosocial TreatmentsTreatments

Page 21: The Pharmacology of Second Generation Neuroleptics

WPAWPA

Psychosocial StrategiesPsychosocial Strategies• Facilitation of pharmcotherapyFacilitation of pharmcotherapy• Token economy systemToken economy system• Carer-based stress managementCarer-based stress management• Living skills trainingLiving skills training• Social case managementSocial case management• Educational Techniques and Family TherapyEducational Techniques and Family Therapy• Cognitive-Behavioral InterventionsCognitive-Behavioral Interventions• Sustaining the benefitsSustaining the benefits